NeuroSense Therapeutics | Investor Presentation Deck

The slide uses a biological mechanism-of-action diagram to illustrate how the two components of PrimeC address specific cellular stressors in ALS.present_solution

Open slide detailBeat · Agitate

The slide uses a combination of a biological process diagram and a pharmacokinetic line chart to demonstrate drug synergy.present_solution

Open slide detailBeat · Solution

The chart uses hazard ratio as a metric for efficacy in an iPSC model derived from ALS patients.show_traction

Open slide detailBeat · Solution

The chart highlights a 'Synchronized concentration peak' at 5 hours for both PrimeC components.present_solution

Open slide detailBeat · Solution

Includes study design parameters (NST002) and key clinical outcomes.show_traction

Open slide detailBeat · Solution

Includes details on screen failures and misdiagnosis exclusions.plan_implementation

Open slide detailBeat · Solution

The slide uses a numbered list format to categorize clinical trial endpoints.present_framework

Open slide detailBeat · Solution

The slide defines the statistical populations used for the clinical trial results.analyze_data

Open slide detailBeat · Solution

other

Open slide detailBeat · Solution

Shows balanced enrollment across key metrics like age, BMI, and disease severity (ALSFRS-R).analyze_data

Open slide detailBeat · Solution

The slide highlights clinical trial safety data for PrimeC.show_traction

Open slide detailBeat · SolutionLoop · Before After

The slide highlights a 37.4% reduction in disease progression with statistical significance (p=0.03) in the per-protocol population, while noting a 29% reductioshow_traction

Open slide detailBeat · SolutionLoop · Before After

The slide uses a list of icons to anchor the clinical impact of the ALSFRS-R scale.establish_context

Open slide detailBeat · SolutionLoop · Cost Of Inaction

The chart visualizes the reduction in points lost, highlighting a 3.22 point difference (p=0.03).show_traction

Open slide detailBeat · SolutionLoop · Cost Of Inaction

The slide uses a human body diagram to categorize ALS symptoms and bar charts to show the reduction in point loss (slower disease progression) for each categoryanalyze_data

Open slide detailBeat · Solution

The chart highlights a 17.2% attenuation in the decline of SVC score for the PrimeC group compared to placebo.show_traction

Open slide detailBeat · Solution

The slide highlights the PARADIGM trial's research pillars, including proteomics, microRNA, exosomes, and neurofilaments, in partnership with institutions like present_solution

Open slide detailBeat · Solution

The slide uses a 'Case Study' to validate the company's own strategy of combination therapy.cite_precedent

Open slide detailBeat · Solution

present_solution

Open slide detailBeat · SolutionLoop · Quick Win Big Bet

The slide presents clinical biomarker data (Aβ40, Aβ42, Tau, pTau, PgJ2) comparing control vs AD groups, analyzed via Mann-Whitney U test.show_traction

Open slide detailLoop · Quick Win Big Bet

The slide outlines the methodology for a Phase 2 clinical trial for Alzheimer's Disease (AD).plan_implementation

Open slide detail

The slide uses a grid layout to present headshots and credentials, with institutional logos aligned below each relevant member.other

Open slide detail

The slide uses a grid layout to display logos of various research and clinical partners.establish_context

Open slide detail

The slide uses a chevron-based timeline to distinguish between past achievements (checkmarks) and future goals (dots).show_traction

Open slide detailBeat · Impact & Next Steps

This is the final slide of the deck.state_next_steps

Open slide detailBeat · Impact & Next Steps

The chart shows a clear divergence between the treatment and placebo groups over time, with error bars indicating variability.show_traction

Open slide detail

The chart highlights a 13.3% difference at the 180-day mark.show_traction

Open slide detail

The table includes adjusted means, 95% confidence intervals, p-values, and percentage differences for various ALS functional domains.analyze_data

Open slide detail